These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39247253)

  • 1. Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Li D; Qin C; Wang H; Du D; Wang Y; Du Q; Liu S
    Ther Adv Drug Saf; 2024; 15():20420986241274909. PubMed ID: 39247253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
    Li D; Wang H; Qin C; Du D; Wang Y; Du Q; Liu S
    Clin Pharmacol Ther; 2024 Mar; 115(3):535-544. PubMed ID: 38069538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
    Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
    Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
    Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
    Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database.
    Li D; Dai L; Zhu J; Wang Y; Zhang R; Wu F; Zhang T; Liu S; Du Q
    Expert Opin Drug Saf; 2024 Aug; ():1-10. PubMed ID: 39175438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database.
    Xia S; Gong H; Zhao Y; Guo L; Wang Y; Ma R; Zhang B; Sarangdhar M; Noguchi Y; Yan M
    Clin Pharmacol Ther; 2023 Jul; 114(1):211-219. PubMed ID: 37086211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database.
    Xia S; Xu JW; Yan KX; Noguchi Y; Sarangdhar M; Yan M
    Front Pharmacol; 2024; 15():1413154. PubMed ID: 39314755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system.
    Liu L; Zhang C; Liu H; Luo H; Cao R; Xiao M; Zou P; Xie Z; Gong H; Ma R; Yan M; Jiang Z
    Expert Opin Drug Saf; 2024 Sep; 23(9):1199-1205. PubMed ID: 38288971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
    Zhou Z; Hultgren KE
    JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
    Li D; Gou J; Zhu J; Zhang T; Liu F; Zhang D; Dai L; Li W; Liu Q; Qin C; Du Q; Liu S
    Front Pharmacol; 2023; 14():1117391. PubMed ID: 37081961
    [No Abstract]   [Full Text] [Related]  

  • 12. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
    Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
    Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of
    Li D; Song Y; Bai Z; Xi X; Liu F; Zhang Y; Qin C; Du D; Du Q; Liu S
    Antibiotics (Basel); 2023 Jun; 12(7):. PubMed ID: 37508205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.
    Li Y; Zhang N; Jiang T; Gan L; Su H; Wu Y; Yang X; Xiang G; Ni R; Xu J; Li C; Liu Y
    Pediatr Neurol; 2024 Sep; 158():71-78. PubMed ID: 38981277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety analysis of therapeutic drugs for breast cancer patients and construction of a predictive model for serious adverse drug reactions.
    Lin S; Lei S; Liu W; Zhu X; Ren B; Feng B
    Eur J Clin Pharmacol; 2024 Feb; 80(2):249-259. PubMed ID: 38099939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system.
    Liu P; He M; Xu X; He Y; Yao W; Liu B
    Seizure; 2023 Aug; 110():203-211. PubMed ID: 37423166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.